Item 5.07 Submission of Matters to a Vote of Security Holders.
Special Meeting of Viveon Health Acquisition Corp.
On December 21, 2022, Viveon Health Acquisition Corp. ("Viveon") called to order
the Special Meeting of its Stockholders (the "Special Meeting") for the purpose
of approving, among other things, the proposed business combination between
Viveon and Suneva Medical, Inc. ("Suneva"). For more information on the Special
Meeting proposals, please refer to the Company's proxy statement/prospectus,
dated November 14, 2022, as supplemented on November 23, 2022. As of November 8,
2022, the record date, there was a total of 10,064,124 shares of common stock
issued and outstanding and entitled to vote at the Special Meeting. Proxies were
received for 8,932,032 shares of common stock, or approximately 88.75% of the
shares issued and outstanding and entitled to vote at the Special Meeting;
therefore a quorum was present. The Special Meeting was adjourned until 10:30
a.m. Eastern Time on January 20, 2023. The Adjournment Proposal received the
following final voting results:
For Against Abstain
8,918,520 13,512 0
Annual Meeting of Viveon Health Acquisition Corp.
Viveon held its 2022 Annual Meeting of Stockholders ("Annual Meeting") at 10:30
a.m. Eastern Time on December 23, 2022 for the purpose of approving: (i) the
Second Extension Proposal; (ii) the Director Election Proposal; (iii) the
Auditor Ratification Proposal; and (iv) the Adjournment Proposal, if needed. For
more information on these proposals, which are described below, please refer to
the Company's proxy statement dated November 17, 2022. As of the record date of
November 8, 2022, there was a total of 10,064,124 shares of common stock issued
and outstanding and entitled to vote at the Annual Meeting. Proxies were
received for 9,685,349 shares of common stock, or approximately 96.24% of the
shares issued and outstanding and entitled to vote at the Annual Meeting;
therefore a quorum was present.
Second Extension Proposal - a proposal to amend the Company's amended and
restated certificate of incorporation, to allow the Company to extend the date
to consummate a business combination on a monthly basis for up to six times by
an additional one month each time for a total of up to six months from
December 28, 2022 until June 30, 2023 (the "Second Extended Date"), upon three
calendar days' advance notice prior to the applicable monthly deadline, unless
the closing of the proposed Business Combination with Suneva Medical Inc., or
any potential alternative initial business combination shall have occurred prior
to the Second Extended Date.
Stockholders voted to approve the Second Extension Proposal. The Second
Extension Proposal received the following final voting results:
For Against Abstain
8,774,530 117,013 0
1
Director Election Proposal - a proposal to re-elect the five current directors
to the Company's Board of Directors.
The five director nominees proposed by the Company's Board of Directors were
each elected to serve as a director until their successors are duly elected and
qualified or until their earlier resignation or removal. The final voting
results for each nominee were as follows:
Nominee For Withheld Broker Non-Vote
Jagi Gill 8,768,135 123,408 793,806
Rom Papadopoulos 8,768,135 123,408 793,806
Demetrios (Jim) G. Logothetis 8,768,135 123,408 793,806
Brian Cole 8,769,135 122,408 793,806
Doug Craft 8,706,263 185,280 793,806
Auditor Ratification Proposal - a proposal to ratify the appointment of Marcum
LLP, as the Company's independent auditors, for the fiscal year ending
December 31, 2021.
Stockholders voted to ratify the appointment of Marcum LLP as the Company's
independent registered certified public accountants for the fiscal year ending
December 31, 2021. The Auditor Ratification Proposal received the following
final voting results:
For Against Abstain
9,683,249 2,100 0
Item 8.01 Other Events
The Company filed a second amendment to its Amended and Restated Certificate of
Incorporation with the Delaware Secretary of State (the "Second Amendment"),
effective as of December 23, 2022, to extend the date to consummate a business
combination until the Second Extended Date, as approved by the Company's
stockholders at the Annual Meeting. A copy of the as-filed Second Amendment is
filed with this Current Report on Form 8-K as Exhibit 3.1.
The Company has deposited the initial payment of $100,000 in its trust account
established at Continental Stock Transfer & Trust Company in connection with its
initial public offering, to initially extend the date by which the Company can
complete an initial business combination by one month to January 28, 2023.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits:
Exhibit Description
3.1 As filed Second Amendment to the Company's Amended and Restated
Certificate of Incorporation.
104 Cover Page Interactive Data File - the cover page XBRL tags are embedded
within the Inline XBRL document.
2
© Edgar Online, source Glimpses